Carisma Therapeutics, Inc.
CARM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $19,632 | $14,919 | $9,834 | $26,544 |
| % Growth | 31.6% | 51.7% | -63% | – |
| Cost of Goods Sold | $59,673 | $74,125 | $0 | $85 |
| Gross Profit | -$40,041 | -$59,206 | $9,834 | $26,459 |
| % Margin | -204% | -396.8% | 100% | 99.7% |
| R&D Expenses | $59,673 | $74,125 | $56,618 | $25,227 |
| G&A Expenses | $20,138 | $29,525 | $9,378 | $0 |
| SG&A Expenses | $20,138 | $29,525 | $9,378 | $29,393 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$57,673 | -$74,125 | $0 | $0 |
| Operating Expenses | $22,138 | $29,525 | $65,996 | $54,620 |
| Operating Income | -$62,179 | -$88,731 | -$56,162 | -$28,161 |
| % Margin | -316.7% | -594.8% | -571.1% | -106.1% |
| Other Income/Exp. Net | $1,702 | $1,852 | -$5,064 | $19,552 |
| Pre-Tax Income | -$60,477 | -$86,879 | -$61,226 | -$8,609 |
| Tax Expense | $0 | $0 | $0 | -$8,273 |
| Net Income | -$60,477 | -$86,879 | -$61,226 | -$336 |
| % Margin | -308.1% | -582.3% | -622.6% | -1.3% |
| EPS | -1.46 | -2.59 | -1.52 | -1.01 |
| % Growth | 43.6% | -70.4% | -50.5% | – |
| EPS Diluted | -1.46 | -2.59 | -1.52 | -1.01 |
| Weighted Avg Shares Out | 41,456 | 33,524 | 40,257 | 9,116 |
| Weighted Avg Shares Out Dil | 41,456 | 33,524 | 40,257 | 9,116 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,702 | $1,936 | $0 | $10 |
| Interest Expense | $0 | $0 | $3,145 | $0 |
| Depreciation & Amortization | $3,354 | $2,837 | $1,893 | $85 |
| EBITDA | -$56,825 | -$85,894 | -$56,188 | -$8,524 |
| % Margin | -289.5% | -575.7% | -571.4% | -32.1% |